

By Nader Bayoumi, MD

Lecturer of Ophthalmology Ophthalmology Department – Alexandria University Alexandria, Egypt

ESG 2012

# Medical Treatment in Pediatric Glaucoma

- Pediatric glaucoma is a surgical disease
- Several options are available for surgery
- Yet, medical therapy still has a role

10/8/2012 ESG - October 2012


• "When **should we use** medical therapy in pediatric glaucoma?"

10/8/2012 ESG - October 2012

# Medical Treatment in Pediatric Glaucoma

 "When should we NOT use medical therapy in pediatric glaucoma?"

10/8/2012 ESG - October 2012



- "When should we use medical therapy in pediatric glaucoma?"
  - Preoperative
    - In preparation for surgery → to clear the cornea to allow goniotomy if this is the procedure planned
    - To manage an accidental delay of surgery (e.g. patient's bad general condition or acute illness, operating room or surgeon availability issues)

10/8/2012 ESG - October 2012

- "When should we use medical therapy in pediatric glaucoma?"
  - Postoperative
    - In the interim between two procedures if the initial surgery fails & the patient is scheduled for another surgery
    - After glaucoma drainage device (GDD) surgery (i.e. in the *hypertensive phase of GDDs*)
    - Permanently after failure of all surgical procedures to adequately control the IOP

10/8/2012 ESG - October 2012

7

# Medical Treatment in Pediatric Glaucoma

- "When should we use medical therapy in pediatric glaucoma?"
  - Permanently if surgical intervention is not
     applicable in a seeing eye, due to →
    - very high risk (e.g Sturge-Weber glaucoma with choroidal hemangioma & a mild elevation of IOP)
    - very poor prognosis (e.g. aphakic/pseudophakic glaucoma with a scarred conjunctiva)
    - both (e.g. aphakic/pseudophakic glaucoma in a vitrectomised eye with advanced optic nerve damage & poor vision)

10/8/2012 ESG - October 2012

- "When should we use medical therapy in pediatric glaucoma?"
  - Permanently if surgical intervention is not applicable in a non-seeing eye (palliative) > therapy may include cycloplegics & steroids mainly, with IOP lowering medications secondarily, specially with time

10/8/2012 ESG - October 2012

9

#### Medical Treatment in Pediatric Glaucoma

- "When should we NOT use medical therapy in pediatric glaucoma?"
  - General → relative
    - Before confirmation of the diagnosis of elevated IOP, by an office examination or by examination under general anaesthesia (EUA), in order not to mask the diagnosis & to allow a proper differential diagnosis
    - Before near term surgery (few days up to I week), in order to facilitate lamellar dissection and/or other surgical procedures on a full –non hypotonous – globe

10/8/2012 ESG - October 2012

- "When should we NOT use medical therapy in pediatric glaucoma?"
  - General → relative
    - Very young patients (infants of few days old)
      due to the small body surface area & body mass
      with resultant mismatch between dose
      administered & patient tolerance
    - Poor general condition, e.g. preterm infants, infants with very low birth weight, infants with severe congenital cardiac, renal or otherwise metabolic anomalies

10/8/2012 ESG - October 2012

11

#### Medical Treatment in Pediatric Glaucoma


- "When should we NOT use medical therapy in pediatric glaucoma?"
  - Drug specific
    - ß blockers
    - α agonists
    - topical carbonic anhydrase inhibitors (CAIs)
    - systemic CAIs
    - prostaglandin analogues (PGAs)
    - Miotics
    - osmotic drugs

10/8/2012 ESG - October 2012

 "What is the <u>treatment plan</u> in pediatric glaucoma?"

10/8/2012 ESG - October 2012

\_\_\_\_



- Precautions & comments
  - evaluate the risks & benefits of the individual medications
  - use the minimum dosage of the medication to achieve a therapeutic benefit
  - monitor children for ocular & systemic side effects
  - in general, the percentage of responders to glaucoma medical therapy ranges from 19 % to 29%, declining with time

10/8/2012 ESG - October 2012

15

# Medical Treatment in Pediatric Glaucoma

 "What are the <u>drugs</u> used for medical therapy of pediatric glaucoma?"

10/8/2012 ESG - October 2012

- "What are the drugs used for medical therapy of pediatric glaucoma?"
  - ß blockers
  - α agonists
  - topical carbonic anhydrase inhibitors (CAIs)
  - systemic CAIs
  - prostaglandin analogues (PGAs)
  - Miotics
  - osmotic drugs

10/8/2012 ESG - October 2012

17

# Medical Treatment in Pediatric Glaucoma

- ß blockers
  - prototype drug: timolol
  - has an IOP lowering effect in almost 30% of treated eyes
  - plasma timolol levels after topical timolol 0.25% in children (specially infants) exceed levels in adults after topical timolol 0.5% (due to volume distribution of the drug) → increased risk of systemic side effects, especially in infants

10/8/2012 ESG - October 2012

- ß blockers
  - reported side effects:
    - reduction in resting pulse rates
    - · apnea (in smaller children)
    - provocation of asthma (?betaxolol)

#### • contraindications & precautions:

- bronchial asthma
- · cardiac disease
- neonates (use with extreme caution)
- recommendation:
  - once daily dosing, of timolol 0.25%, in gel form

10/8/2012 ESG - October 2012

19

# Medical Treatment in Pediatric Glaucoma

- Topical carbonic anhydrase inhibitors (CAIs)
  - prototype: dorzolamide
  - are currently the recommended medical treatment for pediatric glaucoma
  - recommendation:
    - twice daily

10/8/2012 ESG - October 2012

- Systemic CAIs
  - prototype: oral acetazolamide
  - o are safe & well tolerated by children
  - reported side effects:
    - · same side effects as in adults
    - growth suppression
    - · severe metabolic acidosis in infants
  - <u>recommendation</u>:
    - oral acetazolamide, in a dose of 5 15 mg/kg (average 10 mg/kg), given in 3 divided doses

10/8/2012 ESG - October 2012

21

# Medical Treatment in Pediatric Glaucoma

- Prostaglandin analogues (PGAs)
  - prototype: latanoprost
  - more effective in older juvenile onset open angle glaucoma & Sturge-Weber syndrome glaucoma
  - reported side effects:
    - iris pigmentation change
    - eyelash growth
    - hyperemia

10/8/2012 ESG - October 2012

- α-2 agonists
  - prototype: brimonidine
  - IOP lowering range of 7%
  - side effects:

# · central nervous depression

(lipophilic [brimonidine] → cross the blood brain barrier) → extreme fatigue, episodes of coma

 brimonidine should be used with caution in pediatric patients & only used in older children

10/8/2012 ESG - October 2012

23

# Medical Treatment in Pediatric Glaucoma

- Miotics
  - prototype: pilocarpine
  - not effective due to goniodysgenesis & abnormal (anterior) insertion of the ciliary muscle into the trabecular meshwork
  - may be used in aphakic/pseudophakic pediatric glaucoma patients (?debatable)
  - long acting anticholinesterase drugs may induce systemic cholinergic crisis

10/8/2012 ESG - October 2012

- Osmotic drugs
  - prototype: glycerin, mannitol
  - dose:
    - glycerin 0.75 1.5 g/kg body weight, orally, in 50 % solution
    - mannitol (20 % solution) 0.5 1.5 g/kg body weight, intravenously, at approximately 60 drops /minute
  - may be administered <u>preoperatively</u> if IOP remains high even with standard medical therapy

10/8/2012 ESG - October 2012

25

# Thank you